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Background/aim: Preoperative intravenous oxycodone may help to prevent or attenuate intubation-related hemodynamic responses
(IRHRs), but its pharmacokinetics differs according to age and sex. Therefore, we investigated the 95% effective dose (ED95) of intravenous
oxycodone for attenuating all IRHRs, depending on the age and sex of the study population.
Materials and methods: All patients were allocated to one of 6 groups: 1) 20–40 year old males, 2) 41–65yearold males, 3) 66–80 year
old males, 4) 20–40 year old females, 5) 41–65yearold females, and 6) 66–80 year old females (groups YM, OM, EM, YF, OF, and EF,
respectively). Using Dixon’s up-and-down method, the first patient in each group was slowly injected with intravenous oxycodone (0.1
mg kg–1) 20 min before intubation. The subsequent patient received the next oxycodone dose, which was decreased or increased by 0.01
mg kg–1, depending on the “success” or “failure” of attenuation of all IRHRs to within 20% of the baseline values at 1 min after intubation
in the previous patient. After obtaining 8 crossover points, predictive ED95 was estimated with probit regression analysis.
Results: ED95 varied greatly according to age and sex. ED95was 0.133 mg kg–1, 0.181 mg kg–1, 0.332 mg kg–1, 0.183 mg kg–1, 0.108 mg kg–1,
and 0.147 mg kg–1in groups YM, OM, EM, YF, OF, and EF, respectively.
Conclusion: ED95 is higher in males with increasing age but is ambiguous for females. ED95 is higher in males than in females over
40 years of age but is higher in females than in males under 41 years of age. However, after considering the age and sex of the study
population, these results can be used as reference doses for further studies to verify the clinical effects of oxycodone for attenuating all
IRHRs.
Key words: Hemodynamics, humans, intravenous administration, intubation, laryngoscopy, oxycodone

1. Introduction
Direct laryngoscopy and endotracheal intubation
have a risk of undesirable hemodynamic changes,
which may lead to potentially fatal events like cardiac
arrhythmia, cardiac failure, or cerebral hemorrhage,
especially in patients with cardiovascular or cerebral
disease. Therefore, various drug interventions with
local anesthetics, opioids, and other cardiovascular
medicines have been used to attenuate intubationrelated hemodynamic responses (IRHRs) [1].
Opioids are used for preoperative pain control in
approximately 23.1% of patients, most commonly
for those undergoing orthopedic and neurosurgical
procedures [2]. Hydrocodone (59.4%), tramadol
(21.2%), and oxycodone (18.3%) are the most commonly
used opioids [2]. Among them, oxycodone has been
reported to be beneficial in reducing intraoperative

stress reactions, postoperative pain scores, and
postoperative rescue analgesic consumption when it is
administrated in the preoperative period [3–5].
Based on the reduction of intraoperative
stress reactions by oxycodone, we hypothesized
that preoperative intravenous oxycodone may
help to prevent or attenuate IRHRs. Several
studies were conducted to determine the effective
dosage of oxycodone [6–8]. However, despite the
pharmacokinetics of oxycodone varying according to
age and sex [9–11], the oxycodone doses suggested by
these studies have been determined regardless of age
and/or sex [6–8].
We investigated the 95% effective dose (ED95) of
intravenous oxycodone, which could attenuate all
IRHRs to within 20% changes of the baseline values,
depending on the age and sex of our study population.
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2. Materials and methods
We enrolled patients who were between 20–80 years
old, who had an American Society of Anesthesiologists
(ASA) physical status of I or II, and who were scheduled
to undergo elective surgery under general anesthesia.
We excluded patients with chronic opioid medication,
past history of opioid-related complications, recent
medication with a monoamine oxidase inhibitor, renal or
hepatic function abnormalities, cardiopulmonary disease,
neurovascular disease, mental disorders, and all patients
with an ASA status ≥III. We also excluded those patients
for whom successful intubation took longer than 15 s and
all other participants who were deemed vulnerable by the
IRB.
All patients were allocated to 1 of 6 groups according
to sex and age: 1) 20–40 year old males (group YM), 2),
41–65 year old males (group OM), 3) 66–80 year old males
(group EM), 4) 20–40 year old females (group YF), 5)
41–65 year old females (group OF), and 6) 66–80 year old
females (group EF).
After premedication with intramuscular midazolam
(0.05 mg kg–1), the patients were transported to an operating
room. Prior to the induction of anesthesia, standard
patient monitoring devices to obtain electrocardiograms,
noninvasive blood pressure, end-tidal partial pressure

of carbon dioxide, and peripheral pulse oximetry were
applied. We defined the baseline hemodynamic values as
the first values obtained after the patient was taken into
the operating room. The radial artery was cannulated to
obtain continuous blood pressure monitoring. Patients
were premedicated with 0.3 mg ramosetron under
preoxygenation with O2 6 L min–1 via a face maskto
prevent postoperative nausea and vomiting.
We used Dixon’s up-and-down method (Figure 1).
The first patient in each group was slowly injected with
intravenous oxycodone 0.1 mg kg–1 (over 2 min) in the
presence of an experienced anesthesiologist who closely
monitored each patient and ensured their safety and
subsequently intubated them 20 min later. After initiation
of mask ventilation with a 50% oxygen–air mixture,
intravenous propofol (2 mg kg–1) was administered,
followed by the monitoring of anesthetic depth monitoring
(BIS or entropy) and neuromuscular monitoring.
Endotracheal intubation was performed 2 min after the
injection of rocuronium (0.9 mg kg–1) [12]. “Success” or
“failure” of the effect of oxycodone was determined 1 min
after intubation, based on whether the IRHRs significantly
differed from their baseline values. We defined “success” as
a ≤20% change in all of the parameters monitored, namely
the systolic, diastolic, mean arterial pressures (SAP, DAP,

Figure 1. Diagrammatic representation of Dixon’s up-and-down method. SAP: systolic arterial pressure; DAP:
diastolic arterial pressure; MAP: mean arterial pressures; HR: heart rate.
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and MAP, respectively), and heart rate (HR); “failure” was
defined as a >20% change in any of these parameters [12]. The
subsequent patient received the next oxycodone dose, which
was decreased or increased by 0.01 mg kg–1, depending on
the “success” or “failure” of the previous patient, respectively
[12,13]. We repeated Dixon’s up-and-down method until
we obtained 8 crossover points, which were manifested as
crossover from “failure” to “success” [12].
Patients and investigators were blinded to the study
medication, which consisted of the oxycodone dose for
the next patient according to the response of the previous
patient. A noninvestigating nurse loaded the doses into
indistinguishable numbered syringes with the same volume
(5 mL by mixing with normal saline). The syringes were
delivered to the attending anesthesiologist, who was allocated
with a random table generated by a computer, 25 min before
intubation. After endotracheal intubation, the response was
recorded on the injected study medication andwhether the
dose for the next patient would be decreased or increased
was determined. Then, the case report form was delivered to
the noninvestigating nurse.
The age, sex, height, weight, body mass index (BMI),
ASA physical status, SAP, DAP, MAP, and HR was recorded
for each patient.
2.1. Statistical analysis
The primary endpoint was the predictive ED95 of intravenous
oxycodone for attenuating all IRHRs 1 min after intubation.
SPSS (Windows ver. 26.0, IBM Corp., Armonk, NY, USA)
was used for statistical analysis. All measured values of
demographic data are presented as mean (95% confidence
intervals [95% CI]) or as the number of patients.
The chi-square test was used for the analysis of sex and
ASA physical status. The one-way ANOVA, followed by the
Scheffe posthoc test, were used for the analysis of age, height,
weight, and BMI.
The calculated ED50 of intravenous oxycodone was the
mean value of the midpoint doses of all independent pairs
of patients who manifested as a crossover from “failure” to
“success” after 8 crossover points in each group by Dixon’s
upanddown method [12]. The calculated ED50 of intravenous
oxycodone are presented as means (95% CI). The Kruskal–
Wallis test, followed by automatic pairwise comparisons after
Bonferroni correction, was used for analysis of the calculated
ED50 of oxycodone. P values <0.05 were considered to be
statistically significant.
The predictive ED50 and ED95 of intravenous oxycodone
were estimated with a probit regression model. The predictive
ED50 and ED95 of intravenous oxycodone are presented as
predictive values (95% CI).
3. Results
A total of 197 patients (34 patients in group YM, 34 in
group OM, 26 in group EM, 42 in group YF, 27 in group
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OF, and 34 in group EF) were finally enrolled after Dixon’s
upanddown method (Figure 2).
There were significant differences in age, sex, height,
weight, and ASA physical status but not in BMI among the
groups (Table), but this was expected as the patients had
been grouped in terms of age and sex for the study. The
ED50 of oxycodone, which was calculated using Dixon’s
upanddown method, was 0.089 (95% CI, 0.078–0.100)
mg kg–1, 0.156 (95% CI, 0.147–0.166) mg kg–1, 0.134 (95%
CI, 0.109–0.158) mg kg–1, 0.109 (95% CI, 0.101–0.116)
mg kg–1, 0.101 (95% CI, 0.097–0.106) mg kg–1, and 0.091
(95% CI, 0.081–0.101) mg kg–1 in groups YM, OM, EM,
YF, OF, and EF, respectively (Figures 3a–3f and 4). The
calculated ED50 in group YM was significantly lower than
that in groups OM and EM (P < 0.001 and P = 0.028,
respectively). The calculated ED50 in groups YF, OF, and
EF did not show any significant differences between the
groups. The calculated ED50 in group OM was significantly
higher than that in groups OF and EF (P = 0.050 and P =
0.001, respectively). There were no significant differences
between groups YM vs. YF, and groups EM vs. EF.
The predictive oxycodone ED50 from the probit
regression model was estimated as 0.080 [95% CI,
(–0.050)–0.115] mg kg–1, 0.153 (95% CI, 0.142–0.166) mg
kg–1, 0.161 (95% CI, incomputable) mg kg–1, 0.101 (95% CI,
incomputable) mg kg–1, 0.098 (95% CI, 0.093–0.103) mg
kg–1, and 0.080 (95% CI, incomputable) mg kg–1 in groups
YM, OM, EM, YF, OF, and EF, respectively (Figures 5a–5f
and 6).
The predictive oxycodone ED95 from the probit
regression model was estimated as 0.133 (95% CI, 0.106–
2.305) mg kg–1, 0.181 (95% CI, 0.167–0.263) mg kg–1,
0.332 (95% CI, incomputable) mg kg–1, 0.183 (95% CI,
incomputable) mg kg–1, 0.108 (95% CI, 0.103–0.129) mg
kg–1, and 0.147 (95% CI, incomputable) mg kg–1 in groups
YM, OM, EM, YF, OF, and EF, respectively (Figures 5a–5f
and 6).
4. Discussion
This study aimed to evaluate the ED50 and ED95of
intravenous oxycodone for the attenuation of all IRHRs to
within 20% changes of the baseline values, depending on
sex and age of the study population, rather than determine
the clinical effects of these doses. The doses varied (ED50:
0.080–0.161 mg kg–1, ED95: 0.108–0.332 mg kg–1) according
to age and sex. The ED50 and ED95 of oxycodone were
found to be higher in male patients with increasing age
but were ambiguous in female patients.
Several studies have suggested that the effective dose
of oxycodone to minimize IRHRs was above 0.1 mg
kg–1[6–9,12], and intravenous oxycodone above 0.14 mg
kg–1 was as effective as fentanyl 2 µg kg–1, with a lower
complication rate of apnea and less postoperative pain
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Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram. Group YM: males between 20
and 40 years old; group OM: males between 41 and 65 years old; group EM: males between 66 and 80 years
old; group YF: females between 20 and 40 years old; group OF: females between 41 and 65 years old; group
EF: females between 66 and 80 years old.

[7,8,14]. Park et al. [6] found that predictive ED50 andED95
of intravenous oxycodone, obtained with probit analysis
focused on blood pressure, were 0.020 mg kg–1 and 0.159
mg kg–1, respectively, for preventing IRHRs in healthy
patients. Our previous study in male patients also showed
that oxycodone 0.182 mg kg–1 was as effective as fentanyl
2 µg kg–1 despite the predictive ED95 of intravenous
oxycodone being 0.091 mg kg–1 in attenuating all IRHR
changes to less than 20% over the baseline 1 min after
intubation [12]. However, these doses were not sufficient
for attenuating all IRHRs, including heart rate changes.

Intravenous oxycodone below 0.2 mg kg–1 was not
effective in attenuating all IRHRs within a 15% increase
from the baseline [6], and probit analysis with the data
of our previous study also showed that the recalculated
oxycodone ED95 was 0.269 mg kg–1 to prevent all IRHR
changes in male patients [12]. Therefore, intravenous
oxycodone above 0.2 mg kg–1 may be required to attenuate
all IRHRs, including heart rate changes [9].
Oxycodone is known to demonstrate variable
pharmacokinetics that is greatly dependent on age and sex.
The blood concentration, sensitivity, metabolic capacity,
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Table. Demographic and intraoperative data.
Group YM
(n = 34)

Group OM
(n = 34)

Group EM
(n = 26)

Group YF
(n = 42)

Group OF
(n = 27)

Group EF
(n = 34)

P value

Age (years)

29.4
(27.2–31.6)

52.8
(50.1–55.4)

73.5
(71.8–75.2)

27.7
(25.7–29.7)

54.6
(51.6–57.7)

73.6
(71.9–75.3)

< 0.001

Sex (M/F)

34/0

34/0

26/0

0/42

0/27

0/34

< 0.001

Height (cm)

173.4
(171.7–175.0)

168.6
(166.6–170.6)

167.2
(164.6–169.8)

161.7
(160.1–163.4)

156.3
(154.3–158.3)

152.3
(150.3–154.3)

< 0.001

Weight (kg)

74.4
(70.2–78.5)

68.2
(65.4–71.1)

64.9
(61.3–68.4)

63.2
(58.7–67.7)

59.3
(55.6–63.1)

55.5
(52.0–58.9)

< 0.001

BMI (kg (m2) -1)

24.67
(23.48–25.86)

24.02
(23.04–25.00)

23.19
(22.07–24.31)

24.12
(22.51–25.73)

24.22
(22.99–25.44)

23.87
(22.57–25.17)

0.777

ASA_PS (I/II)

32/2

23/11

4/22

34/8

13/14

5/29

< 0.001

The values are expressed as mean (95% confidential intervals) or number of patients. ASA_PS: American Society of Anesthesiologists
physical status; BMI: body mass index. P < 0.05 was considered to indicate statistical significance.

Figure 3. Consecutive dose of intravenous oxycodone during Dixon’s up-and-down. Figures show “success” or “failure” of the effect of
oxycodone 1 min after intubation in group YM (a); group OM (b); group EM (c); group YF (d); group OF (e); and group EF (f). White
circles: “failure”; black circles: “success”.
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Figure 4. ED50 calculated from Dixon’s up-and-down method depending on sex and age. The calculated ED50of oxycodone was 0.089
(95% CI, 0.078–0.100) mg kg–1, 0.156 (95% CI, 0.147–0.166) mg kg–1, 0.134 (95% CI, 0.109–0.158) mg kg–1, 0.109 (95% CI, 0.101–
0.116) mg kg–1, 0.101 (95% CI, 0.097–0.106) mg kg–1, and 0.091 (95% CI, 0.081–0.101) mg kg–1 in groups YM, OM, EM, YF, OF,
and EF, respectively. CI: confidence interval;ED50: effective dose of intravenous oxycodone that could attenuate all intubation-related
hemodynamic response changes to less than 20% over baseline values in 50% of patients. *: P < 0.05, compared with group YM; †:P <
0.05, compared with group OM.

and bioavailability of oxycodone are higher in females than
in males [9–11,15]. With increasing age, oxycodone has
greater bioavailability and lower total body clearance from
plasma [10,11,15]. Therefore, it seems reasonable to titrate
the dose of oxycodone on an individual basis, particularly
in older adults aged above 70 years and in female patients.
A previous clinical study also suggested that the ED50 and
ED95 of intravenous oxycodone for blunting all IRHRs
in adult patients (18–64 years old) were affected by sex
and that male patients (0.324 mg kg–1 and 0.454 mg kg–1)
required 28% more intravenous oxycodone than female
patients (0.254 mg kg–1 and 0.357 mg kg–1) [9]. In this
study, the predictive ED95 of intravenous oxycodone
increased in male patients with increasing age but not in
female patients. The predictive ED95 was higher in older
and elderly male patients than in female patients [9].
However, younger patients (between 20–40 years old) had
a higher predictive ED95 in females than in male patients.
It is difficult to compare our results with those of
previous reports because of study complexities with
different cut-off values (15% vs. 20% change from baseline),
different starting doses for Dixon’s up-and-down method,
and variable study designs (Dixon’s up-and-down method
vs. a randomized controlled study). Firstly, the larger cut-

off value (<20%) used in this study may result in a smaller
effective dose of oxycodone compared with that of studies
that used a 15% change as the cut-off value, which is a
more strict criterion.
Second, Dixon’s up-and-down method demands that
the starting dose should be the minimum dose expected
to result in a positive response [16]. If the choice of
the starting dose is inappropriate, a string of repeated
identical outcomes may occur; eventually, the ED50 may
be much lower or higher than the starting dose. However,
this optimal minimum dose was not known. Therefore,
as a starting dose, we used 0.1 mg kg–1 of intravenous
oxycodone, considering the predictive ED95 (0.091 mg
kg–1) obtained from Goh’s study [12]. Kang et al. opted for
0.2 mg kg–1 in female patients, which was an effective dose
used for the randomized controlled trial studies [7,8] and
a larger dose (0.30 mg kg–1) in male patients [9]. Thus, even
though the same cut-off value might be used, different
starting doses can influence the effective dose obtained
with probit regression from the results of Dixon’s up-anddown method.
Third, the predictive ED50 and ED95 calculated by
Dixon’s up-and-down method and the randomized
controlled trial method may be different. Our previous
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Figure 5. Dose response curves plotted from probit regression analysis. Figures show dose response curves in: all groups (a); male
groups (b); female groups (c); age groups 20 to 40 years (d); age groups 41 to 65 years (e); age groups 66 to 80 years (f).

study in male patients showed that the predictive ED95
of oxycodone calculated with data from Dixon’s up-anddown method was 0.091 mg kg–1, but its actual preventing
effect was 62.2% [12]. From the randomized controlled
study with this predictive ED95, the recalculated predictive
ED95 was 0.269 mg kg–1for attenuating all IRHRs, 0.152
and 0.188 mg kg–1 for attenuating changes of SAP and
MAP, respectively, and0.217 mg kg–1 for attenuating
changes in HR [12]. It was within the 95% CI of ED95 for
attenuating the changes of SAP and MAP in Park’s study,
using less than 15% change as a cut-off level for individual
IRHRs [6].
There are several limitations of this study, as well.
First, we did not exclude hypertensive patients in the
operating room if the patients were of ASA physical status
I or II and were not on any cardiac or antihypertensive
medications. Hypertensive patients are associated with a
marked increase in plasma noradrenaline concentration
and a moderate increase in adrenaline concentration after
intubation, while normotensive patients experience only a
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moderate increase in plasma noradrenaline concentration
without an accompanying change in the plasma
adrenaline concentration [17]. Therefore, hypertensive
patients show a transient increase in sympathetic activity
as a result of increased sensitivity of peripheral vessels
and due to the increased secretion of catecholamines in
response to intubation [18,19]. Consequently, IRHRs are
exaggerated and variable in hypertensive patients when
compared to normotensive patients [18,19]. Second, data
interpretation should be performed from a perspective
of the 95% confidence interval rather than the mean or
representative values, even though the representative
values of ED50 and ED95 seem to be significantly different
or undocumented. If the 95% CIs overlap considerably or
come very close together, this indicates that there is little
or no probability of obtaining a significant differenceat
the P = 0.05 level. In Kang’s study [9], most of the values
had 95% CIs that were either overlapping considerably
or quite close together. Furthermore, this study showed
some results with incomputable 95% CIs. Thus, it was not

SO et al. / Turk J Med Sci

Figure 6. Predictive oxycodone ED50 and ED95 from the probit regression model.The predictive oxycodone ED50 was 0.080 [95% CI,
(–0.050) –0.115] mg kg–1, 0.153 (95% CI, 0.142–0.166) mg kg–1, 0.161 (95% CI, incomputable) mg kg–1, 0.101 (95% CI, incomputable)
mg kg–1, 0.098 (95% CI, 0.093–0.103) mg kg–1, and 0.080 (95% CI, incomputable) mg kg–1 in groups YM, OM, EM, YF, OF, and EF,
respectively. The predictive oxycodone ED95 was 0.133 (95% CI, 0.106–2.305) mg kg–1, 0.181 (95% CI, 0.167–0.263) mg kg–1, 0.332
(95% CI, incomputable) mg kg–1, 0.183 (95% CI, incomputable) mg kg–1, 0.108 (95% CI, 0.103–0.129) mg kg–1, and 0.147 (95% CI,
incomputable) mg kg–1 in groups YM, OM, EM, YF, OF, and EF, respectively. CI: confidence interval; ED50, ED95: effective dose of
intravenous oxycodone that could attenuate all intubation-related hemodynamic response changes to less than 20% over baseline
values in 50% and 95% of patients, respectively.

possible to interpret the significance of these results, if any.
Opioid-induced complications such as hypotension,
bradycardia, and respiratory depression are also
important perioperative concerns at high intravenous
doses of oxycodone. However, doses of up to 0.2 mg
kg–1of oxycodone have shown comparable complications
with fentanyl 2 µg kg–1[7,8].In our study, we did not
observe any oxycodone-related adverseeffects with its
slow administration over 2 min, even at the maximum
dose of 0.16 mg kg–1. Additionally, our patients were on
supplemental oxygen (50% oxygen–air mixture) through
face masks until they were intubated.
In conclusion, the ED50 and ED95 of intravenous
oxycodone for the attenuation of all IRHRs to within 20%
changes of the baseline values varied (ED50: 0.080–0.161
mg kg–1, ED95: 0.108–0.332 mg kg–1) according to the age
and sex of the study population. The ED50 and ED95 of
oxycodone were higher in male patients with increasing age
but were ambiguous in female patients. In addition, ED50
and ED95 of oxycodone were higher in males compared
with females under 40 years of age but higher in females

compared with males over 41 years of age. However, these
dose variations according to the age and sex of the study
population were not statistically significant, and the clinical
impact of these results on the attenuation of all IRHRs, if
any, has yet to be ascertained. Further studies are needed
to verify the clinical effects and complications of multiple
ED95 of oxycodone according to age and sex.
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